DETERMINATION OF CELL SENSITIVITY TO B-Raf INHIBITOR TREATMENT BY DETECTION OF KRAS MUTATION AND RTK EXPRESSION LEVELS

摘要

1. A method for identifying a tumor that is not responding to treatment with a B-Raf inhibitor, comprising determining the expression level of receptor tyrosine kinase (RTK) in a sample obtained from a tumor, wherein aberrant expression or induction of said RTK indicates that said patient will not respond to treatment with said a B-Raf inhibitor, and wherein said tumor expresses B-Raf V600E. 2. The method of claim 1, wherein said RTK is EGFR or cMET. 3. The method of claim 2, further comprising identifying said tumor for treatment by administering an effective amount of: (i) an inhibitor of said EGFR or cMET in combination with a B-Raf inhibitor; and (ii) an MEK inhibitor in combination with a B-Raf. 4 inhibitor. The method of claim 3, wherein said RTK is EGFR, further comprising identifying said tumor for treatment by administering an effective amount of: (i) an inhibitor of said EGFR in combination with a B-Raf inhibitor; or (ii) an MEK inhibitor in combination with a B-Raf.5 inhibitor. The method of claim 3, wherein said RTK is cMET, further comprising identifying said tumor for treatment by administering an effective amount of: (i) an inhibitor of said cMET in combination with a B-Raf inhibitor; or (ii) an MEK inhibitor in combination with a B-Raf inhibitor. 6. The method according to claim 3 (i), 4 (i) or 5 (i), wherein said combination is intended for administration in an additional combination with: (a) an MEK inhibitor; or (b) an ERK inhibitor. 7. The method according to any one of paragraphs. 3 or 4, wherein said EGFR inhibitor is erlotinib. 8. The method of claim 7, wherein said combination is intended to be administered in a synergistic amount. The method of claim 1, wherein said type of tumor is colon cancer